NeuroMetrix Inc.

4.40
0.03 (0.57%)
At close: Mar 03, 2025, 3:59 PM
4.36
-0.91%
After-hours: Mar 03, 2025, 03:59 PM EST

Company Description

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico.

Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.

The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.

NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NeuroMetrix Inc.
NeuroMetrix Inc. logo
Country United States
IPO Date Jul 22, 2004
Industry Medical - Devices
Sector Healthcare
Employees 26
CEO Dr. Shai N. Gozani M.D., Ph.D.

Contact Details

Address:
4B Gill Street
Woburn, Massachusetts
United States
Website https://www.neurometrix.com

Stock Details

Ticker Symbol NURO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001289850
CUSIP Number 641255807
ISIN Number US6412558800
Employer ID 04-3308180
SIC Code 3841

Key Executives

Name Position
Dr. Shai N. Gozani M.D., Ph.D. Founder, Chairman, Chief Executive Officer, President & Secretary
Thomas T. Higgins Senior Vice President, Chief Financial Officer & Treasurer
Dr. Xuan Kong Ph.D. Chief Data Scientist
Susan M. Bell R.N. Senior Vice President of Population Health & Value Based Care

Latest SEC Filings

Date Type Title
Feb 14, 2025 DEFM14A Filing
Feb 13, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 05, 2025 4 Filing
Feb 05, 2025 4 Filing
Feb 05, 2025 4 Filing
Feb 05, 2025 4 Filing
Feb 04, 2025 4/A [Amend] Filing
Feb 03, 2025 4 Filing
Jan 30, 2025 PREM14A Filing
Jan 23, 2025 8-K Current Report